Summary & Overview
HCPCS J3424: Injection, Hydroxocobalamin 25 mg, Intravenous
HCPCS Level II code J3424 denotes an intravenous injection of hydroxocobalamin, 25 mg. This injectable vitamin B12 formulation is used in clinical settings requiring parenteral cyanocobalamin replacement or specific indications where hydroxocobalamin is preferred. Nationally, accurate coding of injectable medications is important for clinical documentation, claims adjudication, and monitoring utilization of infused therapies.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical context and typical sites of service, payer coverage considerations, and the types of benchmarks and policy updates commonly relevant to HCPCS drug codes. The publication outlines expected service lines, common billing modifiers (listed separately), and potential areas of payer policy attention such as prior authorization and billing requirements for infused medications.
This summary equips billing professionals, revenue cycle leaders, and clinicians with a clear understanding of what J3424 represents and where it is typically administered, plus the topics addressed in the full publication: national payer coverage patterns, coding and billing guidance, and clinical context for hydroxocobalamin use. Data not available in the input is noted where applicable in detailed sections.
Billing Code Overview
HCPCS Level II code J3424 describes Injection, hydroxocobalamin, intravenous, 25 mg. The service represents the administration of an injectable form of hydroxocobalamin, a vitamin B12 analogue, provided intravenously.
-
Service type: Intravenous medication administration
-
Typical site of service: Hospital inpatient, hospital outpatient, emergency department, or infusion center where IV medications are administered
Clinical & Coding Specifications
Clinical Context
A patient with documented vitamin B12 deficiency or cyanide exposure presents to an outpatient infusion center or emergency department for intravenous hydroxocobalamin administration. Typical patients include adults with pernicious anemia causing symptomatic B12 deficiency (neuropathy, glossitis, macrocytic anemia) needing urgent parenteral replacement when oral therapy is ineffective or absorption is impaired, and patients with suspected cyanide poisoning (for example following smoke inhalation, house fire, or industrial exposure) requiring immediate antidotal therapy. The clinical workflow: history and indication are confirmed, baseline vital signs and allergy status are reviewed, intravenous access is established, hydroxocobalamin J3424 (25 mg vial) is prepared per institutional protocol, administered IV over the recommended infusion time, and the patient is monitored for infusion reactions and clinical response. Documentation includes indication, lot number, dose administered, route, time, patient tolerance, and any associated procedures (e.g., labs, monitoring). Typical sites of service are outpatient infusion centers, emergency departments, and inpatient medical wards depending on acuity.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Standard reporting when no modifier applies |